Clearmind Medicine Finishes Part A Treatment in FDA Phase I/II Trial for Alcohol Use Disorder
CMND sits 50% above its 52-week low of $2.1.
Summary
Clearmind Medicine has completed treatment for all 24 participants in Part A of its FDA-regulated Phase I/II clinical trial for CMND-100, targeting Alcohol Use Disorder. This follows a 6-K filed on June 16th which announced the completion of dosing for Part A. The company is now assessing the dataset and plans to advance to the next stage if results are favorable. This is a key operational milestone for the small biotech, moving its lead candidate forward.
At the time of this announcement, CMND was trading at $3.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $2.10 to $524.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.